ASX Share rice
Fri 14 Aug 2020 - 09:56:pm (Sydney)

IMU Share Price

IMUGENE LIMITEDIMUPharmaceuticals, Biotechnology & Life Sciences

IMU Company Information

Name:

Imugene Limited

Sector:

Healthcare

Industry:

Biotechnology

GIC Industry:

Biotechnology

GIC Sub Industry:

Biotechnology

Address:

37 Bligh Street Sydney Australia 2000

Phone:

61 3 9824 5254

Exec. Chairman:

Mr. Paul Edward-Alexander Hopper

CEO, MD & Exec. Director:

Ms. Leslie Chong

Chief Technology Officer:

Dr. Nicholas J. Ede

Chief Medical Officer:

Dr. Mark T. Marino

CFO & Joint Company Sec.:

Mr. Phillip Allen Hains

Company Overview:

Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast cancer. The company's HER-Vaxx is in Phase 1b/2 study for gastric cancer. It also engages in developing PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling; and B-Vaxx, a cancer vaccine to treat tumors that over-express the HER2/neu receptor. Imugene Limited was incorporated in 1986 and is headquartered in Sydney, Australia.

IMU Share Price Information

Shares Issued:

4.43B

Market Capitalisation:

$247.85M

Revenue (TTM):

$4.88M

Revenue Per Share (TTM):

$0

Earnings per Share:

$-0.002

Profit Margin:

-1.8695

Operating Margin (TTM):

$-1.93

Return On Assets (TTM):

$-0.11

Return On Equity (TTM):

$-0.19

Quarterly Revenue Growth (YOY):

0.461

Gross Profit(TTM):

$4.13M

Diluted Earnings Per Share (TTM):

$-0.002

IMU CashFlow Statement

CashFlow Date:

2019-06-30

Investments:

$247.39K

Change To Liabilities:

$1.89M

Total Cashflow From Investing Activities:

$247.39K

Net Borrowings:

$-41,143

Net Income:

$-7,775,360

Total Cash From Operating Activities:

$-7,909,490

Depreciation:

$63.26K

Other Cashflow From Investing Activities:

$405.47K

Change To Account Receivables:

$-2,306,636

Sale Purchase Of Stock:

$-1,443,960

Capital Expenditures:

$143.98K

IMU Income Statement

Income Date:

2019-06-30

Income Before Tax:

$-7,775,360

Net Income:

$-7,775,360

Gross Profit:

$4.13M

Operating Income:

$-12,389,033

Interest Expense:

$6.11K

Total Revenue:

$4.13M

Total Operating Expenses:

$12.39M

IMU Balance Sheet

Balance Sheet Date:

2019-06-30

Intangible Assets:

$7.06M

Total Liabilities:

$3.48M

Total Stockholder Equity:

$27.29M

Other Current Liabilities:

$26.75K

Total Assets:

$30.78M

Common Stock:

$63.12M

Other Current Assets:

$160.49K

Retained Earnings:

$-36,816,715

Other Liabilities:

$1M

Other Assets:

$15.59K

Cash:

$19.05M

Total Current Liabilities:

$2.42M

Property - Plant & Equipment:

$233.10K

Net Tangible Assets:

$20.24M

Long-Term Investments:

$50K

Total Current Assets:

$23.42M

Net Receivables:

$4.22M

Short-Term Investments:

$7.36M

Accounts Payable:

$1.48M

Non Currrent Assets (Other):

$15.59K

Short-Term Investments:

$7.36

Non Current Liabilities (Other):

$0.99M

Non Current Liabilities Total:

$1.06M

IMU Share Price History

IMU News

23 May, 2020
The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But on a lighter note, a...
09 Apr, 2020
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
24 Feb, 2020
It is not uncommon to see companies perform well in the years after insiders buy shares. The flip side of that is that...
08 Jan, 2020
Leslie Chong has been the CEO of Imugene Limited (ASX:IMU) since 2016. This report will, first, examine the CEO...
13 Nov, 2019
The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put...
27 Sep, 2019
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...